Tesamorelin vs CJC-1295 with DAC

Tesamorelin and CJC-1295 with DAC are both research peptides investigated for their potential to influence body composition through growth hormone-releasing hormone (GHRH) pathways. Tesamorelin, a synthetic 44-amino-acid analog of human GHRH, has achieved regulatory approval for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, supported by Phase 3 clinical trials. CJC-1295 with DAC, a modified GHRH analog featuring a Drug Affinity Complex that binds to albumin, extends its half-life to approximately 8 days, enabling less frequent dosing. However, this modification results in a continuous growth hormone elevation pattern, which differs from the physiological pulsatile release preserved by Tesamorelin. This comparison highlights their distinct mechanisms, evidence bases, dosing schedules, and safety profiles to guide informed research use.

Tesamorelin (tesamorelin acetate) is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH) and the only FDA-approved medication for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, marketed as Egrifta. It stimulates endogenous GH and IGF-1 production. Egrifta WR, a new weekly-reconstitution formulation, was FDA-approved in March 2025. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy.

Key claims: Reduces visceral adipose tissue in HIV lipodystrophy; Increases skeletal muscle area and density; Effective on INSTI-based HIV regimens.

CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analog incorporating a lysine-linked maleimidopropionic acid moiety that covalently binds to circulating albumin in vivo. This albumin binding extends its half-life from minutes (native GHRH) to approximately 8 days, allowing once- or twice-weekly dosing while maintaining sustained GH elevation. Unlike CJC-1295 without DAC, which preserves pulsatile GH release, the DAC version produces a continuous GH elevation pattern. This is both its advantage (convenience) and disadvantage (non-physiological GH pattern). Preclinical studies indicate improved body composition in animal models, but human evidence remains limited to small-scale trials and anecdotal reports. The evidence level is lower than Tesamorelin, with no FDA approval and a less robust safety database.

Both Tesamorelin and CJC-1295 with DAC are studied for their effects on body composition, particularly in reducing visceral adiposity and increasing lean muscle mass. Tesamorelin's research is predominantly focused on this application, with extensive clinical data in HIV-associated lipodystrophy. CJC-1295 with DAC is also investigated for growth hormone elevation and recovery enhancement, though these areas lack the same depth of evidence. Researchers should note that while Tesamorelin's effects are well-characterized in human trials, CJC-1295 with DAC's applications are more exploratory, often in preclinical or small-scale human studies. The shared focus on body composition underscores the potential of GHRH analogs, but the evidence disparity requires careful interpretation.

Tesamorelin: Common adverse events in clinical trials include injection site reactions (17%), arthralgia (13%), myalgia (6%), and peripheral edema (6%). Headache, nausea, and flu-like symptoms are also reported. Blood glucose monitoring is recommended in diabetic patients due to potential increases in glucose levels. Overall, it is generally well-tolerated over 26-week therapy periods. CJC-1295 with DAC: Reported side effects include water retention and edema, particularly facial puffiness, as well as numbness and tingling in extremities, consistent with sustained GH elevation. Joint pain is also noted. The safety profile is less thoroughly characterized due to limited human data, and the non-physiological GH pattern may pose theoretical risks, such as acromegaly-like effects with prolonged use. Researchers should exercise caution in experimental settings.